SOURCE-LINKED STUDY SUMMARY
Anti-Müllerian Hormone and Metabolic Dysfunction in Polycystic Ovary Syndrome: A Cross-Sectional Study with Age-Stratified Analysis and BMI Mediation
Abstract summarizedQuality not appraised
- What was studied
- Whether anti-Müllerian hormone adds information about metabolic risk in polycystic ovary syndrome.
- Who / model studied
- A single-center cross-sectional study of 123 women with polycystic ovary syndrome, including 43 adolescents and 80 reproductive-aged women.
- Studied dose & schedule
- Dose and schedule were not reported in the source used for this summary.
- What the study found
- Higher hormone levels correlated with lower body mass index and LDL cholesterol, but higher testosterone. Its association with insulin resistance weakened after adjusting for body mass index. A model adding hormones and age did not clearly outperform body mass index alone.
- Limitations & context
- Cross-sectional associations do not establish a causal pathway. The prediction model still needs validation in other patient groups.
Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.21203/rs.3.rs-10842224/v1